April 07, 2016
5 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: PCKS9 inhibitors effective for reducing CV risk
BOSTON — Robert Eckel, MD, professor of medicine in the divisions of endocrinology, metabolism and diabetes and of cardiology at the University of Colorado School of Medicine, discusses his presentation on the use of PCKS9 inhibitors in clinical practice.
According to Eckel, years ago, there were very few drugs for patients at risk for cardiovascular disease, but there is now substantial evidence that statins reduce CV risk.
Eckel said it is important to understand the 2013 American Heart Association and American College of Cardiology guidelines on statins before prescribing them to patients.